KLRA (KLRA) Stock Price & Analysis
KLRA (KLRA) fell 0.30% to USD 19.64 as of June 10, 2026 at 09:53 UTC, according to Nexqual real-time market data.
KLRA last closed at USD 19.7; the session ranged USD 19.11–20.22 on volume of 573,789 shares. Market capitalization is $2.54B, with a 52-week range of USD 18.85–28.23 (NMS). Source: Nexqual, June 10, 2026 at 09:53 UTC.
Key Statistics (as of June 10, 2026 at 09:53 UTC)
| Price | USD 19.64 |
|---|---|
| Change | ▼ 0.30% (down) |
| Previous Close | USD 19.7 |
| Open | USD 19.68 |
| Day Range | USD 19.11 – 20.22 |
| 52-Week Range | USD 18.85 – 28.23 |
| Volume | 573,789 shares |
| Market Cap | $2.54B |
| Exchange | NMS |
Technical Analysis (KLRA)
Nexqual's technical model rates KLRA "SELL" based on 1 bullish and 3 bearish signals across 36 daily candles, as of June 10, 2026 at 09:53 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 36.35 (neutral) |
| MACD | -0.92 (negative) |
Analyst Ratings (KLRA)
Wall Street analysts rate KLRA "Strong Buy" based on 5 analysts, with a mean price target of USD 42.6 (range USD 30–57), per Nexqual as of June 10, 2026 at 09:53 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 42.6 |
| High Target | USD 57 |
| Low Target | USD 30 |
| Buy / Hold / Sell | 6 / 0 / 0 |
Earnings (KLRA)
| Next Earnings Date | 2026-08-07 |
|---|---|
| EPS Estimate | USD -0.72 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -3.65 vs est -0.55 ▼ miss |
Source: Nexqual, June 10, 2026 at 09:53 UTC.
Financials & Fundamentals (KLRA)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -36.90% |
| Current Ratio | 12.02 |
| Free Cash Flow | $-59.89M |
Source: Nexqual, June 10, 2026 at 09:53 UTC.
Financial Health Score (KLRA)
Nexqual rates KLRA's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 09:53 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — No data |
| Cash Flow | Weak — Operating cash flow -$120M |
| Efficiency | Critical — ROE -37%, ROA -22.7% |
Ownership (KLRA)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +42.31% |
| Shares Outstanding | 129.57M |
| Float | 8,662 |
| Short % of Float | +2.07% |
Source: Nexqual, June 10, 2026 at 09:53 UTC.
Leadership (KLRA)
KLRA is led by Ronald C. Renaud Jr. (age 56), President, CEO & Director, per Nexqual as of June 10, 2026 at 09:53 UTC.
| President, CEO & Director | Ronald C. Renaud Jr. (age 56) |
|---|---|
| Chief Operating & Business Officer | Paul Douglas Burgess J.D., M.S. (age 51) |
| Chief Financial Officer | Douglas W. Pagan (age 53) |
| Vice President of Corporate Communications & Investor Relations | Maura Gavaghan |
Major Backers & Investors (KLRA)
Notable institutional backers of KLRA include Fidelity, according to Nexqual as of June 10, 2026 at 09:53 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 2.09% |
Source: Nexqual, June 10, 2026 at 09:53 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ALMR | Alamar Biosciences, Inc. | USD 20.13 | ▼ 2% |
| SPTX | Seaport Therapeutics, Inc. | USD 17.66 | ▲ 7.42% |
| COAG | Hemab Therapeutics Holdings, In | USD 27 | ▲ 6.72% |
| MANE | Veradermics, Incorporated | USD 95.91 | ▲ 4.6% |
| AVLN | Avalyn Pharma Inc. | USD 28.67 | ▲ 5.95% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 09:53 UTC. This page is informational and not investment advice.